Resolution WHA67.21 on access to biotherapeutic products including similar biotherapeutic products and ensuring their quality, safety and efficacy, urges Member States:

• To develop or strengthen national regulatory assessment and authorization frameworks, to meet the needs for biologicals, including biosimilars
• To develop the necessary scientific expertise to facilitate development of solid, scientifically-based regulatory frameworks that promote access to products that are affordable, safe, efficacious and of high quality
• To ensure that new national regulations do not create barriers to access to quality, safe, efficacious and affordable biologicals, including biosimilars

The resolution comes as a result of the fact that WHO acknowledges that biosimilars ‘could be more affordable and offer better access to treatments of biological origin, while ensuring quality, safety and efficacy’.

Generics and biosimilars advocate the European Generic medicines Association (EGA) welcomed WHO’s resolution on access to biologicals and biosimilars. EGA’s Director General, Mr Adrian van den Hoven, commented that ‘these resolutions constitute important milestones for patients worldwide as they aim to support national drug regulatory authorities, particularly in developing countries, to strengthen their regulatory systems, while promoting equitable access to quality, safe, efficacious, and affordable medical products.’

Related article

Global guidelines for biosimilars

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.